Scancell Holdings plc has agreed to acquire Neuphoria Therapeutics in an all-share transaction that will position the combined company for a Nasdaq listing while strengthening its financial resources to advance late-stage cancer immunotherapy development. The deal, supported by up to $89 million in financing, is designed to fund the Phase 3 clinical program for Scancell’s lead melanoma candidate, iSCIB1+, and expand access to U.S. capital markets.
Scancell Holdings plc has announced an agreement to acquire Neuphoria Therapeutics Inc. in an all-share merger that will create a Nasdaq-listed oncology biotechnology company focused on advancing immunotherapy treatments for cancer. Following completion of the transaction, the combined organization intends to operate under the Scancell name and apply to trade on Nasdaq under the proposed ticker symbol SCLT.
The merger represents more than a corporate restructuring. It reflects a strategic effort by Scancell to secure broader access to U.S. institutional investors and the world’s largest biotechnology capital market as it prepares to move its lead immunotherapy candidate into a pivotal Phase 3 clinical trial.
Alongside the merger, Scancell expects to secure up to $89 million through a combination of equity financing, debt facilities, and Neuphoria’s existing cash balance. The funding package includes $39.1 million in private placement commitments from new and existing investors, a planned $12 million UK placing, a retail offering of up to $3 million, and a non-binding debt financing term sheet of up to $25 million with funds and accounts managed by BlackRock. Neuphoria is also expected to contribute at least $10 million in cash upon closing.
Together, the financing is expected to provide sufficient capital to support Scancell’s registrational Phase 3 trial for iSCIB1+, extending the combined company’s projected cash runway into 2029.
Nasdaq Listing Supports Clinical Development Strategy
For biotechnology companies developing innovative therapies, access to U.S. capital markets has become increasingly important as clinical programs grow more expensive. Nasdaq remains the preferred exchange for many life sciences companies because of its specialist healthcare investor base and higher levels of biotechnology investment compared with many regional exchanges.
Scancell’s planned Nasdaq listing is intended to increase visibility among U.S. investors while providing additional financing flexibility as its clinical programs advance.
The company’s lead asset, iSCIB1+, is being developed as an immunotherapy for advanced melanoma. The investigational therapy has received Fast Track designation from the U.S. Food and Drug Administration (FDA), a regulatory pathway intended to accelerate the development and review of medicines addressing serious medical conditions with unmet clinical needs.
According to the company, results from the ongoing Phase 2 SCOPE trial demonstrated 77% progression-free survival at 22 months when iSCIB1+ was administered alongside the immune checkpoint inhibitors ipilimumab and nivolumab. Additional progression-free survival and overall survival data are expected within the next year and could help shape the design and regulatory positioning of the planned Phase 3 study.
Financing Reflects Continued Investor Interest in Oncology Innovation
The financing package accompanying the merger highlights continued investor support for oncology despite a more selective biotechnology funding environment over the past two years. While venture investment has moderated across parts of the life sciences sector, investors have continued backing clinical-stage companies with differentiated assets and clearly defined regulatory pathways.
The proposed financing structure also combines multiple capital sources—including private placements, retail participation, institutional debt, and merger-related cash resources—providing greater flexibility than relying solely on public equity issuance.
The involvement of BlackRock through a non-binding debt financing term sheet signals institutional interest in supporting later-stage biotechnology development, although completion remains subject to definitive agreements and customary closing conditions.
Strategic Value Beyond Capital Markets
Beyond financing, the merger offers strategic benefits for both companies.
For Scancell, the transaction accelerates its transition into a U.S.-focused biotechnology company while strengthening its balance sheet ahead of a pivotal clinical milestone. For Neuphoria shareholders, the agreement provides continued exposure to Scancell’s oncology pipeline while preserving potential future value from certain partnered Neuphoria assets through contingent value rights (CVRs).
Scancell Chief Executive Officer Dr. Phil L’Huillier said the Nasdaq listing would provide access to the capital needed to execute the registrational Phase 3 study, adding that the company’s Phase 2 data support advancing iSCIB1+ into randomized late-stage clinical evaluation.
Neuphoria Chairman Alan Fisher said the transaction offers shareholders an opportunity to participate in the long-term value creation associated with Scancell’s immunotherapy portfolio while maintaining potential upside tied to Neuphoria’s partnered assets.
Why the Deal Matters
The transaction illustrates a broader trend across the biotechnology industry, where companies increasingly pursue cross-border mergers to access deeper capital pools, expand investor visibility, and accelerate clinical development.
According to Evaluate Pharma, oncology remains the largest therapeutic area by global pharmaceutical sales, while IQVIA projects continued growth in oncology research investment driven by advances in immunotherapy, precision medicine, and combination treatments. At the same time, McKinsey & Company has noted that access to sufficient late-stage financing is becoming a critical differentiator for biotech companies progressing toward commercialization.
For enterprise healthcare investors and the broader biotechnology ecosystem, the Scancell-Neuphoria merger represents a financing strategy designed to bridge promising mid-stage clinical data with the substantial capital requirements of late-stage drug development. Whether the combined company can translate encouraging Phase 2 results into successful Phase 3 outcomes will ultimately determine the long-term impact of this transaction on patients, investors, and the competitive oncology landscape.
Market Landscape
The global oncology market continues to attract significant investment as immunotherapies become central to cancer treatment strategies. Evaluate Pharma forecasts oncology will remain the world’s largest pharmaceutical market over the coming decade, while IQVIA estimates global oncology medicine spending will continue rising as innovative biologics and combination therapies enter late-stage development.
At the same time, biotech firms increasingly seek Nasdaq listings to access specialist healthcare investors capable of funding expensive Phase 3 clinical trials. Strategic mergers and diversified financing structures have become common approaches for companies preparing for regulatory submissions and commercialization.
Top Insights
- Scancell will acquire Neuphoria through an all-share merger, creating a Nasdaq-focused oncology company positioned to expand access to U.S. biotechnology investors and capital markets.
- The combined company expects to secure up to $89 million through equity, debt financing, and existing cash to support Phase 3 development of iSCIB1+.
- Scancell’s lead immunotherapy candidate has received FDA Fast Track designation and demonstrated encouraging Phase 2 progression-free survival results in advanced melanoma.
- The transaction reflects broader biotechnology trends in cross-border mergers, late-stage clinical financing, and strategic Nasdaq listings to support commercialization.
- Investors will closely monitor upcoming Phase 2 survival data and the planned Phase 3 registrational study as key milestones for the combined company.
Join thousands of HR leaders who rely on HRTechEdge for the latest in workforce technology, AI-driven HR solutions, and strategic insights
